588 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates http://www.zacks.com/stock/news/357341/aduro-adro-q4-earnings-and-revenues-fall-shy-of-estimates?cid=CS-ZC-FT-357341 Feb 28, 2019 - Wider-than-expected loss affects Aduro (ADRO) in the fourth quarter. Also, revenues lag estimates.
United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates http://www.zacks.com/stock/news/357300/united-therapeutics-uthr-q4-earnings-sales-beat-estimates?cid=CS-ZC-FT-357300 Feb 28, 2019 - United Therapeutics (UTHR) beats estimates for both earnings and sales in the fourth quarter. Stock up.
Corcept (CORT) Q4 Earnings Beat Estimates, Revenues In Line http://www.zacks.com/stock/news/357024/corcept-cort-q4-earnings-beat-estimates-revenues-in-line?cid=CS-ZC-FT-357024 Feb 26, 2019 - Corcept (CORT) earnings beat estimates in the fourth quarter of 2018 on increased revenues.
Merck to Buy Immunotherapy Developer Immune Design for $300M http://www.zacks.com/stock/news/356654/merck-to-buy-immunotherapy-developer-immune-design-for-%24300m?cid=CS-ZC-FT-356654 Feb 22, 2019 - Merck (MRK) plans to acquire Immune Design for $300 million in cash. Merck will pay $5.85 in cash for each share of Immune Design.
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates http://www.zacks.com/stock/news/356445/pharma-stock-roundup-mrk-buys-imdz-fda-grants-priority-review-to-some-candidates?cid=CS-ZC-FT-356445 Feb 22, 2019 - Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review http://www.zacks.com/stock/news/356394/dow-30-stock-roundup-wmt-earnings-beat-mrks-keytruda-sbla-gets-priority-review?cid=CS-ZC-FT-356394 Feb 22, 2019 - The index endured a holiday-shortened but volatile week.
Allergan Responds to Investor's Call for CEO/Chair Role Split http://www.zacks.com/stock/news/355578/allergan-responds-to-investors-call-for-ceo-chair-role-split?cid=CS-ZC-FT-355578 Feb 20, 2019 - Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.
Eli Lilly and Co (LLY) Files 10-K for the Fiscal Year Ended on December 31, 2018 http://www.gurufocus.com/news/818630/eli-lilly-and-co-lly-files-10k-for-the-fiscal-year-ended-on-december-31-2018 Feb 19, 2019 - Eli Lilly and Co (LLY) Files 10-K for the Fiscal Year Ended on December 31, 2018, Stocks: LLY, release date:Feb 19, 2019
Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo http://www.zacks.com/stock/news/355437/bayer-obtains-full-rights-to-vitrakvi-from-lillys-loxo?cid=CS-ZC-FT-355437 Feb 19, 2019 - Bayer (BAYRY) obtains full exclusive licensing rights for the global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from Loxo.
Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice http://www.zacks.com/stock/news/355011/are-you-looking-for-a-high-growth-dividend-stock-eli-lilly-lly-could-be-a-great-choice?cid=CS-ZC-FT-355011 Feb 15, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Pages: 123456789101112...59

<<<Page 7>